Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

Clinics in Louisiana

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

What Louisiana law means for peptide clinics: who may prescribe, whether pharmacies may compound GLP-1 drugs (limited), how to check a clinic, and listings with their verification status.

Louisiana at a glance

Pharmacy regulator
Louisiana Board of Pharmacy
503A framework
Follows the federal 503A framework
Telehealth prescribing
Regulatory: Telehealth allowed
Asynchronous prescribing
Regulatory: Async not allowed
Compounded GLP-1 access
Regulatory: Compounded GLP-1 limited

Clinics serving Louisiana

No verified clinics serving Louisiana are listed yet. A provider appears here only after it passes the verification checklist, and those checks are still under way.

Looking for care now? Start with what the law allows where you live, then how a legitimate prescription works.

Run a pharmacy, clinic, or telehealth service? Apply for a listing.

Peptide access rules in Louisiana

Yes. A Louisiana resident can obtain FDA approved peptides such as semaglutide and tirzepatide by prescription from a physician licensed to practice medicine in Louisiana (La. R.S. 37:1271), and the Louisiana Telehealth Access Act (La. R.S. 40:1223.4) says a provider is not required to conduct an in-person history or exam before a telehealth encounter for non-controlled drugs. The Board of Medical Examiners rule still defines telemedicine as a live, two-way interaction, so a prescription cannot rest on an online message exchange alone. For obesity treatment and weight management, Act 345 of 2026 protects telehealth only when the provider conducts a synchronous (live) interaction with the patient. Compounded peptides are available when eligible under federal 503A rules and dispensed by a Louisiana pharmacy or a nonresident pharmacy holding a Louisiana Board of Pharmacy permit (La. R.S. 37:1232). The Louisiana Board of Pharmacy was one of the first boards, in 2023, to tell pharmacies to stop compounding with semaglutide salt forms and to stop shipping such products into the state. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [21]

Compounded GLP-1 access in Louisiana

In spring 2023, while semaglutide was still in shortage, the Louisiana Board of Pharmacy told in-state compounders to stop compounding semaglutide made from unapproved salt forms (such as semaglutide sodium or acetate) and told out-of-state compounders not to ship such products into Louisiana; the Board's director clarified that compounding with the approved base form was not banned at the time. Since the FDA shortage allowances ended in 2025, compounded semaglutide and tirzepatide are limited to documented patient-specific needs in Louisiana as elsewhere. Act 345 of 2026 protects telehealth for obesity and weight management only when the provider conducts a live, synchronous interaction, and the Board of Medical Examiners rule against telemedicine for obesity treatment remains enforceable against care with no live interaction. [1] [13] [14] [15] [19]

Research use only sellers in Louisiana

Only Louisiana-permitted pharmacies, including nonresident pharmacies permitted under La. R.S. 37:1232, may dispense prescription drugs to Louisiana patients. The Louisiana Board of Pharmacy has described semaglutide salt forms sold as "research use only" as not intended for human use, and "research use only" peptides sold for injection are unapproved new drugs under federal law. [8] [15] [20]

Louisiana notes on specific peptides

  • Semaglutide: Available branded by prescription. The Louisiana Board of Pharmacy warned in 2023 against compounding with semaglutide salt forms and against shipping such products into Louisiana, and compounded semaglutide base is limited to documented patient-specific needs since the 503A grace period ended April 22, 2025. [15] [19]
  • Tirzepatide: Available branded by prescription, including by live telemedicine from a physician licensed in Louisiana. The Board of Medical Examiners rule defines telemedicine as simultaneous two-way video and audio. Act 345 of 2026 protects telehealth for obesity and weight management only when the provider conducts a synchronous interaction. Compounded tirzepatide is limited to documented patient-specific needs since the 503A grace period ended February 18, 2025. [3] [13] [14] [19]
  • BPC-157: Not FDA approved and not on the 503A bulks list; its nomination was withdrawn in April 2026. On October 28, 2026 HHS released a draft enforcement discretion policy covering single-ingredient BPC-157 compounded by a state-licensed pharmacy by an allowed route, on a patient-specific prescription, from an FDA-registered manufacturer's tested substance, with serious adverse events reported to FDA. It is not an FDA approval, is not binding, and does not cover blends such as Wolverine. FDA's drug center recommended against listing; the advisory committee voted in favor (HHS policy, Appendix B). The Louisiana Board of Pharmacy has not issued a BPC-157 specific rule, and its stated position is that compounders may use only bulk substances that meet federal requirements. Act 374 of 2026 (La. R.S. 37:23.5) bars Louisiana licensing boards from prohibiting peptide compounding that complies with section 503A, but BPC-157 is still not eligible under 503A until FDA adds it to the bulks list, so state limits still apply alongside the HHS draft. [15] [17] [18] [21] [22] [23]

How to check a clinic in Louisiana

  1. Confirm the prescribing clinician's license with the Louisiana medical or nursing board.
  2. Ask which pharmacy compounds or dispenses the peptide and check it in the Louisiana Board of Pharmacy license lookup. [1] [8] [9] [10] [11] [12] [15] [16] [21]
  3. Confirm the peptide can be lawfully compounded: check its status on the regulatory tracker or its peptide page before paying.
  4. Walk away from any seller that labels a peptide "research use only" or "not for human consumption". See the research use only section above for what that means in Louisiana. [8] [15] [20]

Common questions in Louisiana

Does Louisiana let out-of-state doctors prescribe by telemedicine?

Only with Louisiana authorization. La. R.S. 37:1271 requires a Louisiana license to practice medicine, except as the Louisiana Telehealth Access Act provides. The separate telemedicine license statute (R.S. 37:1276.1) was repealed effective January 1, 2024, and R.S. 40:1223.4 now calls for board rules on licensing or registration of out-of-state telehealth providers. Check the Louisiana State Board of Medical Examiners lookup. [2] [3] [4] [6]

Do I need an in-person visit before a telemedicine GLP-1 prescription in Louisiana?

Not an in-person visit, but a live one. La. R.S. 40:1223.4 says a provider is not required to conduct an in-person history or exam before a telehealth encounter, though the same standard of care applies. The in-person requirement applies to controlled dangerous substances, and GLP-1 drugs are not controlled. The Board of Medical Examiners rule defines telemedicine as simultaneous two-way video and audio and says an online, electronic or written mail message does not meet the standard of care, so a message exchange alone is not enough. For obesity or weight management, Act 345 of 2026 protects telehealth only when the provider conducts a live, synchronous interaction with you. [6] [7] [13] [14]

All peptide legal questions for Louisiana

Sources

  1. [1]Louisiana Board of Pharmacy
  2. [2]Louisiana State Board of Medical Examiners
  3. [3]La. R.S. 37:1271, License to practice medicine required (Louisiana State Legislature, text effective January 1, 2024)
  4. [4]Louisiana Act 322 of 2023 (Senate Bill 66), telehealth: amends R.S. 37:1262(4), 37:1271 and 40:1223.3 to 1223.5, repeals R.S. 37:1276.1
  5. [5]La. R.S. 40:1223.3, Louisiana Telehealth Access Act definitions (Louisiana State Legislature)
  6. [6]La. R.S. 40:1223.4, Telehealth; rulemaking required (Louisiana State Legislature)
  7. [7]Louisiana Administrative Code Title 46, Part XLV, section 7503, Telemedicine definitions (LSBME rules)
  8. [8]La. R.S. 37:1232, Nonresident pharmacy
  9. [9]Louisiana Board of Pharmacy: Title 37, chapter 14, Pharmacy Practice Act
  10. [10]Louisiana Administrative Code Title 46, Part LIII, Pharmacists (Board of Pharmacy rules)